COMP vs MAC

Compass, Inc. exhibits significant fundamental weakness, highlighted by a Piotroski F-Score of 3/9, placing it in the 'Weak' health category. While the company maintains strong top-line revenue growth of 23.10% and a low Price/Sales ratio of 0.84, these are offset by negative profit margins, a negative ROE of -9.79%, and a concerning liquidity position with a current ratio of 0.86. There is a stark disconnect between the bullish analyst target price of $13.25 and the internal reality of consistent earnings misses (0/4 beats in the last year) and aggressive insider selling by the CFO and General Counsel.

The Macerich Company exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health. Despite a recent price rally, the company suffers from negative profit margins, shrinking year-over-year revenue (-17.40%), and a severe liquidity crunch with a current ratio of 0.45. The dividend is unsustainable with a payout ratio of 188.89%, and the forward P/E is deeply negative, suggesting significant earnings distress. The disconnect between the 'Buy' analyst consensus and the deterministic health scores suggests a high-risk speculative environment.